GenScript's life science business offers IVT RNA and LNP-related services. Its ProBio subsidiary provides CGT CMC services including mRNA vaccines and nucleic acid drugs. Entity information uses GenScript group-level data.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public financial snapshot
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
Period
Currency / basis
Revenue
Net profit
Operating cash flow
Report
FY2025 2025-12-31
USD HKFRS / consolidated
959,526,000
-532,830,000 Net income/(loss) attributable to owners of the parent
Consolidated group financials; not standalone CRO/CDMO segment revenue.
Source unit: USD thousands; multiplied by 1000 to show absolute amounts.
Year-over-year changes were calculated from current/prior-period source amounts and rounded to two decimals. Conventional earnings growth is not shown for a negative prior-period base or a change from profit to loss.
The listed group includes life science services and products, ProBio CRDMO and industrial synthetic biology. Group revenue is not standalone ProBio CDMO revenue.
Legend Biotech’s deconsolidation generated a substantial gain in 2024. The 2025 reported parent-attributable loss includes equity-method losses and impairment related to Legend; adjusted earnings must not replace reported results.
The company’s promoted H1 2026 revenue growth of +27.3% is an underlying comparison excluding the prior-year LaNova licensing transaction. Reported revenue was USD 518.773 million in the prior period and USD 404.216 million in the current period, a reported decline of -22.08%.
2026H1 · Reporting notes
Consolidated group financials; not standalone CRO/CDMO segment revenue.
Source unit: USD thousands; multiplied by 1000 to show absolute amounts.
Year-over-year changes were calculated from current/prior-period source amounts and rounded to two decimals. Conventional earnings growth is not shown for a negative prior-period base or a change from profit to loss.
The listed group includes life science services and products, ProBio CRDMO and industrial synthetic biology. Group revenue is not standalone ProBio CDMO revenue.
Legend Biotech’s deconsolidation generated a substantial gain in 2024. The 2025 reported parent-attributable loss includes equity-method losses and impairment related to Legend; adjusted earnings must not replace reported results.
The company’s promoted H1 2026 revenue growth of +27.3% is an underlying comparison excluding the prior-year LaNova licensing transaction. Reported revenue was USD 518.773 million in the prior period and USD 404.216 million in the current period, a reported decline of -22.08%.
Adjusted net income growth is calculated from reported USD-thousand amounts of 62523/177973. The company’s 203.3% growth figure is on an underlying basis and is not mixed with reported figures.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
GenScript's life science business offers IVT RNA and LNP-related services. Its ProBio subsidiary provides CGT CMC services including mRNA vaccines and nucleic acid drugs. Entity information uses GenScript group-level data.
Principal platforms include life science services/products, ProBio biologics and advanced-therapy CRDMO, and Bestzyme industrial synthetic biology.
Listed as HKEX 01548; original 2025 annual and 2026H1 reports reviewed.
Program / service
Target / indication
Representative stage
Evidence & scope
RNA / LNP service capabilities
Project-dependent / not verified · Project-dependent / not verified
Services / platform
This record does not establish human validation of the entire platform
Life science products/services / ProBio CRDMO
Not applicable (services/platform) · Drug research and manufacturing services for clients
Services / platform
Not applicable: service capabilities are not clinical drug candidates; E4 does not rate service quality.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.
Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.
Service scope and candidates reflect the cited disclosures. Project pricing, turnaround time, available capacity, and technology licensing terms require further confirmation.
Financials are consolidated figures for the listed group. Revenue by service line, available capacity, and project fit require further verification at the segment and operating-entity levels.
Proprietary products/licensing and research services operate in parallel. Distinguish business lines; group profit does not establish the quality of a specific service.
